Advanced search

  • Cardiology Journal
  • Online first Treatment of dyslipidemia in Poland — common diagnostics, early combined therapy. Expert position statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. 5th Declaration of Sopot
Online first
Experts' Viewpoint
Published online: 2025-03-31

open access

View PDF Download PDF file
Supp./Additional Files
Page views 110
Article views/downloads 53
Get Citation

Connect on Social Media

Connect on Social Media

Treatment of dyslipidemia in Poland — common diagnostics, early combined therapy. Expert position statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. 5th Declaration of Sopot

Marcin Wełnicki1, Iwona Gorczyca-Głowacka2, Agnieszka Kapłon-Cieślicka3, Maciej Janiszewski4, Jarosław D. Kasprzak5, Przemysław Leszek6, Anna Tomaszuk-Kazberuk7, Maria Łukasiewicz1, Mariusz Tomaniak3, Stanisław Surma8, Agnieszka Mickiewicz9, Krzysztof Narkiewicz10, Miłosz Jaguszewski11, Zbigniew Krasiński12, Daniel Śliż1, Artur Mamcarz1, Filip M. Szymański13, Marcin Barylski14, Beata Wożakowska-Kapłon15, Krzysztof J. Filipiak1617
DOI: 10.5603/cj.103680
Pubmed: 40162986

Abstract

Not available

Keywords: cardiovascular riskstainsezetimibeprimary preventionsecondary preventionmetabolic syndrome

Article available in PDF format

View PDF Download PDF file

References

  1. Filipiak KJ, Cybulska B, Dudek D, et al. Current problems of dyslipidemia therapy in Poland - Sopot Declaration. Expert position supported by the Cardiovascular Pharmacotherapy Section of the Polish Cardiac Society. Cardiovascular Diseases. 2011; 8: 1–4.
  2. Wożakowska-Kapłon B, Filipiak K, Mamcarz A, et al. Actual problems of dyslipidaemia treatment in Poland — 2nd Declaration of Sopot. Experts’ Group Consensus endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. Kardiologia Polska. 2014; 72(9): 847–853.
    CrossRef
  3. Szymański FM, Barylski M, Cybulska B, et al. Recommendation for the management of dyslipidemia in Poland - Third Declaration of Sopot. Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. Cardiol J. 2018; 25(6): 655–665.
    CrossRefPubMed
  4. Szymański FM, Mickiewicz A, Dzida G, et al. Management of dyslipidemia in Poland: Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. The Fourth Declaration of Sopot. Cardiol J. 2022; 29(1): 1–26.
    CrossRefPubMed
  5. Mach F, Baigent C, Catapano AL, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111–188.
    CrossRefPubMed
  6. Banach M, Burchardt P, Chlebus K, et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci. 2021; 17(6): 1447–1547.
    CrossRefPubMed
  7. Pająk A, Szafraniec K, Polak M, et al. WOBASZ Investigators. Changes in the prevalence, treatment, and control of hypercholesterolemia and other dyslipidemias over 10 years in Poland: the WOBASZ study. Pol Arch Med Wewn. 2016; 126(9): 642–652.
    CrossRefPubMed
  8. Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE Investigators. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016; 23(6): 636–648.
    CrossRefPubMed
  9. Kotseva K, De Backer G, De Bacquer D, et al. EUROASPIRE Investigators*. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019; 26(8): 824–835.
    CrossRefPubMed
  10. Zdrojewski T, Solnica B, Cybulska B, et al. Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey. Kardiol Pol. 2016; 74(3): 213–223.
    CrossRefPubMed
  11. Jóźwiak JJ, Studziński K, Tomasik T, et al. LIPIDOGRAM2015 Investigators. The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study. Atheroscler Suppl. 2020; 42: e15–e24.
    CrossRefPubMed
  12. Gańczak M, Miazgowski T, Kożybska M, et al. Changes in disease burden in Poland between 1990-2017 in comparison with other Central European countries: A systematic analysis for the Global Burden of Disease Study 2017. PLoS One. 2020; 15(3): e0226766.
    CrossRefPubMed
  13. De Backer G, Jankowski P, Kotseva K, et al. EUROASPIRE V collaborators, Writing Committee, Scientific Steering/ Executive Committee, Coordinating centre, Diabetes centre, Data management centre, Statistical analysis centre, Central laboratory, Study centres, organisations, investigators and other research personnel (National Co-ordinators in each country are indicated by asterisk. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019; 285: 135–146.
    CrossRefPubMed
  14. Jankowski P, Kozieł P, Setny M, et al. Dyslipidemia Management in Patients with Coronary Artery Disease. Data from the POLASPIRE Survey. J Clin Med. 2021; 10(16).
    CrossRefPubMed
  15. Jankowski P, Koczwarska-Maciejek D, Kamiński K, et al. Implementation of the cardiovascular prevention guidelines in clinical practice. Results from the POLASPIRE II survey. Kardiol Pol. 2025 [Epub ahead of print].
    CrossRefPubMed
  16. Mickiewicz A, Chmara M, Futema M, et al. Efficacy of clinical diagnostic criteria for familial hypercholesterolemia genetic testing in Poland. Atherosclerosis. 2016; 249: 52–58.
    CrossRefPubMed
  17. Rynkiewicz A, Cybulska B, Banach M, et al. Polish Lipid Expert Forum. [Management of familial heterozygous hypercholesterolaemia. Position paper of the Polish Lipid Expert Forum]. Kardiol Pol. 2013; 71(1): 107–111.
    PubMed
  18. Knowles JW, Rader DJ, Khoury MJ. Cascade Screening for Familial Hypercholesterolemia and the Use of Genetic Testing. JAMA. 2017; 318(4): 381–382.
    CrossRefPubMed
  19. Sharifi M, Futema M, Nair D, et al. Polygenic Hypercholesterolemia and Cardiovascular Disease Risk. Curr Cardiol Rep. 2019; 21(6): 43.
    CrossRefPubMed
  20. Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41(2): 255–323.
    CrossRefPubMed
  21. Visseren FLJ, Mach F, Smulders YM, et al. ESC National Cardiac Societies, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227–3337.
    CrossRefPubMed
  22. Marx N, Federici M, Schütt K, et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023; 44(39): 4043–4140.
    CrossRefPubMed
  23. SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J. 2023; 44(28): 2544–2556.
    CrossRefPubMed
  24. Stone NJ, Smith SC, Orringer CE, et al. Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022; 79(8): 819–836.
    CrossRefPubMed
  25. Raitakari OT, Magnussen CG, Juonala M, et al. Subclinical atherosclerosis in young adults predicting cardiovascular disease: The Cardiovascular Risk in Young Finns Study. Atherosclerosis. 2024; 393: 117515.
    CrossRefPubMed
  26. An J, Zhang Y, Zhou H, et al. Incidence of Atherosclerotic Cardiovascular Disease in Young Adults at Low Short-Term But High Long-Term Risk. J Am Coll Cardiol. 2023; 81(7): 623–632.
    CrossRefPubMed
  27. Agbaje AO. Increasing lipids with risk of worsening cardiac damage in 1595 adolescents: A 7-year longitudinal and mediation study. Atherosclerosis. 2024; 389: 117440.
    CrossRefPubMed
  28. Masrouri S, Tamehri Zadeh SS, Shapiro MD, et al. Impact of optimal cholesterol levels on subclinical atherosclerosis in the absence of risk factors in young adults. Atherosclerosis. 2024; 393: 117520.
    CrossRefPubMed
  29. Devesa A, Ibanez B, Malick WA, et al. Primary Prevention of Subclinical Atherosclerosis in Young Adults: JACC Review Topic of the Week. J Am Coll Cardiol. 2023; 82(22): 2152–2162.
    CrossRefPubMed
  30. Lechner K, von Schacky C, McKenzie AL, et al. Lifestyle factors and high-risk atherosclerosis: Pathways and mechanisms beyond traditional risk factors. Eur J Prev Cardiol. 2020; 27(4): 394–406.
    CrossRefPubMed
  31. van Oort S, Beulens JWJ, van Ballegooijen AJ, et al. Association of Cardiovascular Risk Factors and Lifestyle Behaviors With Hypertension: A Mendelian Randomization Study. Hypertension. 2020; 76(6): 1971–1979.
    CrossRefPubMed
  32. Schmidt-Trucksäss A, Lichtenstein AH, von Känel R. Lifestyle factors as determinants of atherosclerotic cardiovascular health. Atherosclerosis. 2024; 395: 117577.
    CrossRefPubMed
  33. Osadnik T, Goławski M, Lewandowski P, et al. A network meta-analysis on the comparative effect of nutraceuticals on lipid profile in adults. Pharmacol Res. 2022; 183: 106402.
    CrossRefPubMed
  34. Trogkanis E, Karalexi MA, Sergentanis TN, et al. Safety and Efficacy of the Consumption of the Nutraceutical "Red Yeast Rice Extract" for the Reduction of Hypercholesterolemia in Humans: A Systematic Review and Meta-Analysis. Nutrients. 2024; 16(10).
    CrossRefPubMed
  35. Langhi C, Vallier M, Bron A, et al. A polyphenol-rich plant extract prevents hypercholesterolemia and modulates gut microbiota in western diet-fed mice. Front Cardiovasc Med. 2024; 11: 1342388.
    CrossRefPubMed
  36. Arsenault BJ, Kamstrup PR. Eight reasons why lipoprotein(a) should be measured in everyone at least once in a lifetime. Eur Heart J. 2024; 45(30): 2692–2694.
    CrossRefPubMed
  37. Sosnowska B, Stepinska J, Mitkowski P, et al. Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels. Arch Med Sci. 2024; 20(1): 8–27.
    CrossRefPubMed
  38. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022; 43(39): 3925–3946.
    CrossRefPubMed
  39. Surma S, Sosnowska B, Reiner Ž, et al. New data allow to better understand the secrets of lipoprotein(a): is that for sure? Eur Heart J Open. 2024; 4(5): oeae066.
    CrossRefPubMed
  40. Surma S, Zembala MO, Okopień B, et al. Lipoprotein (a) and lipid-lowering treatment from the perspective of a cardiac surgeon. An impact on the prognosis in patients with aortic valve replacement and after heart transplantation. Int J Cardiol Cardiovasc Risk Prev. 2024; 22: 200297.
    CrossRefPubMed
  41. Dobrowolski P, Prejbisz A, Kuryłowicz A, et al. Metabolic syndrome - new definition and management in practice. Position statement of PTNT, PTLO, PTL, PTH, PTMR, PTMSŻ, the Prevention and Epidemiology section of PTK, the "30 Club" of PTK and the Metabolic and Bariatric Surgery section of TChP. Hypertension in Practice. 2022; 8(2): 47–72.
  42. Gorczyca-Głowacka I, Wełnicki M, Mamcarz A, et al. Metabolic associated fatty liver disease and cardiovascular risk: The expert opinion of the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society. Kardiol Pol. 2023; 81(2): 207–214.
    CrossRefPubMed
  43. Rinella ME, Lazarus JV, Ratziu V, et al. NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023; 78(6): 1966–1986.
    CrossRefPubMed
  44. Ibanez B, Fernández-Ortiz A, Fernández-Friera L, et al. Progression of Early Subclinical Atherosclerosis (PESA) Study: JACC Focus Seminar 7/8. J Am Coll Cardiol. 2021; 78(2): 156–179.
    CrossRefPubMed
  45. Tristão-Pereira C, Fuster V, Oliva B, et al. Longitudinal interplay between subclinical atherosclerosis, cardiovascular risk factors, and cerebral glucose metabolism in midlife: results from the PESA prospective cohort study. Lancet Healthy Longev. 2023; 4(9): e487–e498.
    CrossRefPubMed
  46. Vrints C, Andreotti F, Koskinas KC, et al. ESC Scientific Document Group. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024; 45(36): 3415–3537.
    CrossRefPubMed
  47. Braunwald E. Triglycerides: the past, the present, and the future. Eur Heart J. 2024; 45(37): 3780–3781.
    CrossRefPubMed
  48. Giugliano RP, Pedersen TR, Park JG, et al. FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017; 390(10106): 1962–1971.
    CrossRefPubMed
  49. Gaba P, O'Donoghue ML, Park JG, et al. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. Circulation. 2023; 147(16): 1192–1203.
    CrossRefPubMed
  50. Patti G, Spinoni EG, Grisafi L, et al. Safety and efficacy of very low LDL-cholesterol intensive lowering: a meta-analysis and meta-regression of randomized trials. Eur Heart J Cardiovasc Pharmacother. 2023; 9(2): 138–147.
    CrossRefPubMed
  51. Duprez D, Jacobs DR. LDL-cholesterol lowering: to be or not to be too low. Eur J Prev Cardiol. 2023; 30(12): 1205–1206.
    CrossRefPubMed
  52. Averna M, Banach M, Bruckert E, et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis. 2021; 325: 99–109.
    CrossRefPubMed
  53. Hong SJ, Jeong HS, Ahn JC, et al. A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial. Clin Ther. 2018; 40(2): 226–241.e4.
    CrossRefPubMed
  54. Soleimani H, Mousavi A, Shojaei S, et al. Safety and Effectiveness of High-Intensity Statins Versus Low/Moderate-Intensity Statins Plus Ezetimibe in Patients With Atherosclerotic Cardiovascular Disease for Reaching LDL-C Goals: A Systematic Review and Meta-Analysis. Clin Cardiol. 2024; 47(8): e24334.
    CrossRefPubMed
  55. Kim BK, Hong SJ, Lee YJ, et al. RACING investigators. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022; 400(10349): 380–390.
    CrossRefPubMed
  56. Mahajan K, Nagendra L, Dhall A, et al. Impact of early initiation of ezetimibe in patients with acute coronary syndrome: A systematic review and meta-analysis. Eur J Intern Med. 2024; 124: 99–107.
    CrossRefPubMed
  57. Ray KK, Aguiar C, Arca M, et al. SANTORINI Study Investigators. Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study. Eur J Prev Cardiol. 2024; 31(15): 1792–1803.
    CrossRefPubMed
  58. Jun JiE, Jeong IK, Ahn KJ, et al. Combination of low- or moderate-intensity statin and ezetimibe vs. high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study. Eur J Prev Cardiol. 2024; 31(10): 1205–1213.
    CrossRefPubMed
  59. Koren MJ, Rodriguez F, East C, et al. An "Inclisiran First" Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. 2024; 83(20): 1939–1952.
    CrossRefPubMed
  60. Goodman SG, Steg PG, Szarek M, et al. ODYSSEY OUTCOMES Investigators. Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation. Eur Heart J Cardiovasc Pharmacother. 2024; 10(4): 342–352.
    CrossRefPubMed
  61. Rajtar-Salwa R, Bobrowska B, Socha S, et al. Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk. Medicina (Kaunas). 2024; 60(7).
    CrossRefPubMed
  62. Wright RS, Raal FJ, Koenig W, et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovasc Res. 2024; 120(12): 1400–1410.
    CrossRefPubMed
  63. Samuel E, Watford M, Egolum UO, et al. Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol. Ann Pharmacother. 2023; 57(3): 317–324.
    CrossRefPubMed
  64. Cai T, Abel L, Langford O, et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ. 2021; 374: n1537.
    CrossRefPubMed
  65. Nissen SE, Menon V, Nicholls SJ, et al. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients. JAMA. 2023; 330(2): 131–140.
    CrossRefPubMed
  66. Connelly-Smith L, Alquist CR, Aqui NA, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. J Clin Apher. 2023; 38(2): 77–278.
    CrossRefPubMed
  67. Pottle A, Thompson G, Barbir M, et al. Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989-2017. Atherosclerosis. 2019; 290: 44–51.
    CrossRefPubMed
  68. Mickiewicz A, Marlega J, Kuchta A, et al. Cardiovascular events in patients with familial hypercholesterolemia and hyperlipoproteinaemia (a): Indications for lipoprotein apheresis in Poland. J Clin Apher. 2021; 36(3): 370–378.
    CrossRefPubMed
  69. Schettler VJJ, Schettler E. Beyond cholesterol-pleiotropic effects of lipoprotein apheresis. Ther Apher Dial. 2022; 26 Suppl 1: 35–40.
    CrossRefPubMed
  70. Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24): 2545–2559.
    CrossRefPubMed
  71. Zhu L, Hayen A, Bell KJL. Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study. Cardiovasc Diabetol. 2020; 19(1): 28.
    CrossRefPubMed
  72. Bernasconi AA, Lavie CJ, Milani RV, et al. Omega-3 Benefits Remain Strong Post-STRENGTH. Mayo Clin Proc. 2021; 96(5): 1371–1372.
    CrossRefPubMed
  73. Jia X, Gao F, Pickett JK, et al. Association Between Omega-3 Fatty Acid Treatment and Atrial Fibrillation in Cardiovascular Outcome Trials: A Systematic Review and Meta-Analysis. Cardiovasc Drugs Ther. 2021; 35(4): 793–800.
    CrossRefPubMed
  74. Kim NH, Kim JiY, Choi J, et al. Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study. Eur Heart J Cardiovasc Pharmacother. 2024; 10(2): 118–127.
    CrossRefPubMed
  75. Surma S, Mikhailidis DP, Banach M. Celebrating the 90th birthday of the scientist who discovered statins: Akira Endō. Eur Heart J. 2024; 45(9): 647–650.
    CrossRefPubMed
  76. Surma S, Burchardt P, Banach M. Hypolipemic drugs. In: Cardiology. Handbook of the Polish Society of Cardiology. Editorial. Mitkowski P., Gil R., Witkowski A., Lipiec P. 2nd ed. Via Medica. 2023: 132–140.
  77. Surma S, Shapiro MD, Banach M. Breaking new ground in lipid management: Insights from the 2024 American College of Cardiology Scientific Sessions. Pharmacol Res. 2024; 205: 107246.
    CrossRefPubMed
  78. Banach M, Surma S. A look to the past - what has had the biggest impact on lipids in the last four decades? A personal perspective. Arch Med Sci. 2023; 19(3): 559–564.
    CrossRefPubMed
  79. Banach M, Surma S, Toth PP, et al. endorsed by the International Lipid Expert Panel (ILEP). 2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024? Arch Med Sci. 2023; 19(6): 1602–1615.
    CrossRefPubMed
  80. Banach M, Surma S, Kapłon-Cieślicka A, et al. Position paper of the Polish Expert Group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association. Arch Med Sci. 2024; 20(1): 28–42.
    CrossRefPubMed
  81. Gu J, Gupta RN, Cheng HK, et al. Current treatments for the management of homozygous familial hypercholesterolaemia: a systematic review and commentary. Eur J Prev Cardiol. 2024; 31(15): 1833–1849.
    CrossRefPubMed
  82. Banach M, Reiner Ž, Surma S, et al. International Lipid Expert Panel (ILEP). 2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP). Drugs. 2024; 84(12): 1541–1577.
    CrossRefPubMed
  83. Herrera Martínez A, Palomares Ortega R, Bahamondes Opazo R, et al. Hyperlipidemia during gestational diabetes and its relation with maternal and offspring complications. Nutr Hosp. 2018; 35(3): 698–706.
    CrossRefPubMed
  84. Preda A, Preda SD, Mota M, et al. Dyslipidemia in Pregnancy: A Systematic Review of Molecular Alterations and Clinical Implications. Biomedicines. 2024; 12(10).
    CrossRefPubMed
  85. Connelly-Smith L, Alquist CR, Aqui NA, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. J Clin Apher. 2023; 38(2): 77–278.
    CrossRefPubMed
  86. Marlęga-Linert J, Gąsecka A, van der Pol E, et al. Lipoprotein apheresis affects the concentration of extracellular vesicles in patients with elevated lipoprotein (a). Sci Rep. 2024; 14(1): 2762.
    CrossRefPubMed
  87. Mickiewicz A, Marlęga-Linert J, Czapiewska M, et al. Fatty acid analysis in serum of patients with elevated lipoprotein(a) and cardiovascular disease undergoing lipoprotein apheresis. J Clin Lipidol. 2024; 18(2): e197–e206.
    CrossRefPubMed
  88. Reijman MD, Kusters DM, Groothoff JW, et al. Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN. Atherosclerosis. 2024; 392: 117525.
    CrossRefPubMed
  89. Cuchel M, Raal FJ, Hegele RA, et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023; 44(25): 2277–2291.
    CrossRefPubMed
  90. Schumann F, Kassner U, Spira D, et al. Long-term lipoprotein apheresis reduces cardiovascular events in high-risk patients with isolated lipoprotein(a) elevation. J Clin Lipidol. 2024; 18(5): e738–e745.
    CrossRefPubMed
  91. Kronenberg F. Lipoprotein(a): from Causality to Treatment. Curr Atheroscler Rep. 2024; 26(3): 75–82.
    CrossRefPubMed
  92. Kastelein JJP, Hsieh A, Dicklin MR, et al. Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments. Curr Atheroscler Rep. 2024; 26(2): 35–44.
    CrossRefPubMed
  93. Giammanco A, Spina R, Cefalù AB, et al. APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism. Curr Atheroscler Rep. 2023; 25(3): 67–76.
    CrossRefPubMed
  94. Agnello F, Ingala S, Laterra G, et al. Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management. J Clin Med. 2024; 13(5).
    CrossRefPubMed
  95. Michaeli DT, Michaeli JC, Albers S, et al. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. Am J Cardiovasc Drugs. 2023; 23(5): 477–495.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2025 Via Medica Regulations Cookie policy Privacy Statement Legal Note